In a pivotal study of 100 CKD stage 4 patients with hyperphosphatemia (> 6.0 mg/dL) (11), it was demonstrated that Sevelamer but not calcium acetate was able to reduce FGF23 and improve endothelial function (11). Here, FGF23 is linked to hyperphosphatemia.